Title: MK-0677 (ibutamoren mesylate) for treatment of patients recovering from hip fracture
A multicenter, randomized, placebo-controlled Phase IIb clinical trial investigating MK‑677 in elderly patients after hip fracture.
Outcomes included mobility, bone healing, and functional recovery. Reddit+15PubMed+15Reddit+15
Title: Effects of MK‑677 on somatic growth, GH/IGF‑1 axis and body composition in elderly subjects
Daily 10–25 mg dosing in adults 64–81 years old showed up to 97% increase in GH and 88% in IGF‑1.
Increased lean body mass by approximately 3 kg with no change in fat mass. Raised insulin and prolactin levels modestly. PubMed+5PMC+5Wikipedia+5Wikipedia
Title: Short‑term MK‑677 treatment increases markers of bone turnover in obese males
In healthy men with BMI > 30, 25 mg/day for 8 weeks induced significant increases in bone formation and resorption markers (e.g., osteocalcin, IGFBP‑5). PubMed+1chemdatabank.com+1
Title: MK‑677 in mild to moderate Alzheimer’s disease: 12‑month randomized trial
563 patients received 25 mg/day or placebo for a year. IGF‑1 increased significantly, but no improvement in cognitive or functional outcomes was observed. Reddit+15PubMed+15PMC+15
Title: Effect of MK‑677 on somatic growth in rats
Animal model confirming GH secretagogue activity and studying metabolic effects and safety endpoints in lab rodents. chemdatabank.com+2PubMed+2PubMed+2
$100.00 Original price was: $100.00.$80.00Current price is: $80.00.
29 in stock
Provided by Combat Research – Research-Grade Peptides
CAS Number: 159634-47-6
Other Names: MK-0677, L-163,191, Oratrope
IUPAC Name:
2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4′-piperidine]-1′-yl)-1-oxo-3-(phenylmethoxy)propan-2-yl]propanamide mesylate
Molecular Formula: C₂₇H₃₆N₄O₅S·CH₃SO₃H
Molecular Weight: 624.77 g/mol
MK-677 (Ibutamoren) is a non-peptide, orally active growth hormone secretagogue under ongoing investigation for its ability to increase growth hormone (GH) and IGF-1 levels. At Combat Research, we offer 20mg dry fill powder capsules for research use only, specifically designed for consistency, purity, and ease of dosing in controlled laboratory environments.
This formulation is ideal for studies related to:
Muscle preservation during energy deficit
Endocrine system regulation under operational stress
Age-related hormonal decline and metabolism research
Performance resilience in tactical or combat models
Form: Dry Fill Powder Capsules
Concentration: 20 mg per capsule
Appearance: Off-white to light tan powder in clear or opaque gelatin capsule
Purity: ≥98% (HPLC Tested)
Grade: Research Use Only (RUO)
Each unit is securely packaged with tamper-evident seals and produced under strict lab handling standards to maintain stability and prevent cross-contamination.
This product is intended solely for research purposes, including but not limited to:
University-based hormone studies
Military and tactical performance R&D
Public and private laboratory research involving endocrine responses
Cited in studies found on PubMed, NIH.gov, and ClinicalTrials.gov.
NOT approved by the FDA for human or veterinary use
Supplied for Research Use Only per 21 CFR 312.2(b)
No therapeutic or diagnostic claims are made or implied
Sale is restricted to qualified labs, institutions, or licensed professionals
Disclaimer: MK-677 (Ibutamoren) capsules sold by Combat Research are for laboratory research only and are not for human consumption. This product is not a drug, food, or dietary supplement and should not be used in any clinical or therapeutic application. All buyers must be qualified professionals or institutions. Use of this product in any manner not consistent with its labeling may violate federal law.
Only logged in customers who have purchased this product may leave a review.
$165.00 Original price was: $165.00.$129.00Current price is: $129.00.
$35.99 Original price was: $35.99.$27.99Current price is: $27.99.
$75.00 Original price was: $75.00.$60.00Current price is: $60.00.
$80.00 Original price was: $80.00.$65.00Current price is: $65.00.
Reviews
There are no reviews yet.